Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KT-621 in Uncontrolled Moderate to Severe Eosinophilic Asthma
NCT07323654Phase 2Recruiting
- Sponsor
- Kymera Therapeutics
- Start
- Jan 2026
- Primary completion
- Dec 2027
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 13
01
Overview
A Phase 2 trial of KT-621 in eosinophilic asthma (EA), sponsored by Kymera Therapeutics. Started Jan 2026; status: recruiting.
02
Drugs
KT-621
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on NCT07323654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07323654.